Silvia Forroova is the director of Partnerships & Sustainability for the CPHI portfolio at Informa Markets. With more than 18 years of experience in global events, she specializes in strategic partnerships within the pharmaceutical industry.

Silvia leads sustainability initiatives across the CPHI portfolio of events, developing strategies that drive positive environmental impact for trade events and the wider pharmaceutical industry. She is also the founder of the Sustainability Collective, an impact network that brings together change-makers from across the pharmaceutical industry to foster collaboration, share insights, and drive tangible progress on sustainability challenges.

Videos

In part 2 of this 2-part interview, Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, tells PharmTech about the challenges in achieving sustainability in pharma and how the CPHI Sustainability Summit, which launches at CPHI Milan 2026, can help organizations tackle these challenges.

CPHI Milan Puts Sustainability to Work, Part 2

This week, a $2.3 billion manufacturing campus and a new fill-finish platform signal capacity is crucial; AI in pharma is still evolving; and CPHI Milan previews a new Sustainability Summit.

PharmTech Weekly Roundup—August 14, 2026

Articles

FDA approves TAUKLARIFY, a tau PET imaging agent for Alzheimer's, adding a biomarker tool that could shape trial design for drug developers.

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

Lee Karras, CEO, Halo discusses the company's new sterile fill-finish platform, Apotex partnership, and injectable onshoring strategy.

Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?

Brian Drapeau is founder, GxPFrame and a cell and gene therapy manufacturing and quality systems consultant.
He can be contacted at bdrapeau@gxpframe.com for any consulting or advisory needs. 

EMA’s draft GMP Annex 22 sidelines LLMs in critical manufacturing, fueling a push for risk-based guardrails and human accountability.

Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.

PharmTech spoke with Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, about the new Sustainability Summit that will launch at CPHI Milan 2026 and how it can help organizations obtain measurable, commercially viable solutions for sustainability in the pharma industry.

CPHI Milan Puts Sustainability to Work, Part 1

Jordan Xu is an engineering expert specializing in automated pharmaceutical manufacturing systems. He is currently with DROFEN MACHINERY EQUIPMENT CO., LTD, a leading system supplier of turnkey automated assembly lines for insulin pens and aseptic filling systems for PFS. With extensive experience in resolving fill-finish bottlenecks, DROFEN partners with global CDMOs to deliver GMP-compliant, high-speed production solutions that accelerate time-to-market.

Pen injector pre-assembly demands 160 PPM precision: LVDT/vision systems, tolerance control, and GAMP5 challenge testing ensure ISO 11608 compliance.

Engineering High-Speed Pen Injector Pre-Assembly Machine: Overcoming Dimensional Variability in Multi-Component Mechanism Integration

Senior Director
Education, Outreach, and Digital Experience
Open Biopharma Research and Training Institute

Richard Jaenisch, Open Biopharma breaks down AI's real limits in drug discovery, agent security risks, and what workforce readiness looks like by 2028.

Q&A: AI Coding Tools Carry the Real Risk

Sentynl and Mereo's alvelestat deal for AATD-LD signals early manufacturing collaboration ahead of phase 3, shifting care from IV to oral therapy.

Alvelestat Deal Signals Early Manufacturing Push for AATD-LD

Glenn Herring, Technical Operations Consultant, Halo

Glenn Herring, Halo Pharma, details the CDMO's new sterile fill-finish platform, Groninger/SKAN tech, GMP/Annex 1 design, and 2026 qualification timeline.

News